{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:44:05Z","timestamp":1791333845129,"version":"4.3.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":288,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In September 2018, the World Health Organization recommended that prevaccination screening be used with the tetravalent dengue vaccine (CYD-TDV), to ensure that only individuals with evidence of prior dengue infection (PDI) are vaccinated. Dengue rapid diagnostic tests (RDTs) would offer a potential solution for prevaccination screening at the point-of-care, but data on performance of available RDTs for identifying PDI are limited. We determined the suitability of four dengue RDTs and two conventional enzyme-linked immunosorbent assays (ELISAs) to identify PDI and evaluated cross-reactivity with co-circulating flaviviruses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Methods: Specificity was assessed using 534 dengue-negative [determined by 50% plaque reduction neutralization test (PRNT50)] serum samples from USA (n\u2009=\u2009229) and dengue-endemic regions (n\u2009=\u2009305). Sensitivity was assessed using 270 samples from recent (n\u2009=\u200990) or remote (n\u2009=\u200990) virologically confirmed prior dengue cases, and dengue PRNT50-positive samples (n\u2009=\u200990). Cross-reactivity was assessed in dengue-seronegative samples that were seropositive for yellow fever (n\u2009=\u200957), Japanese encephalitis (n\u2009=\u200937), West Nile (n\u2009=\u200959) or Zika (n\u2009=\u200941).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Results: Dengue IgG RDTs and the Panbio ELISA exhibited favourable specificities (99\u2013100%), higher than the Focus ELISA (95%). The RDTs had variable sensitivities (40\u201370%) that were lower than those of the ELISAs (\u226590%). Cross-reactivity to other flaviviruses was low with RDTs (\u22647%), but more significant with ELISAs (up to 51% for West Nile and 34% for Zika). No cross-reactivity to any of the four closely related flaviviruses was observed with the CTK Biotech RDT. For each SeroTest, sensitivity appeared similar in samples from individuals with recent (&amp;lt;13\u00a0months) vs remote (3\u20134\u00a0years) virologically confirmed PDI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Conclusions: In general, dengue IgG RDTs were found to be more specific and less cross-reactive than the ELISAs, but the latter were more sensitive for identifying PDI cases. Currently available RDTs could be temporizing tools for rapid and safe prevaccination screening until improved RDTs with increased sensitivity become available.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taz078","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T07:33:34Z","timestamp":1571038414000},"source":"Crossref","is-referenced-by-count":48,"title":["Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection"],"prefix":"10.1093","volume":"26","author":[{"given":"Matthew","family":"Bonaparte","sequence":"first","affiliation":[{"name":"Global Clinical Immunology, Sanofi Pasteur, 1 Discovery Drive, Swiftwater PA 18370, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Global Biostatistics, Sanofi Pasteur, 1 Discovery Drive, Swiftwater PA 18370, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Garg","sequence":"additional","affiliation":[{"name":"Global Clinical Immunology, Sanofi Pasteur, 1 Discovery Drive, Swiftwater PA 18370, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guy","sequence":"additional","affiliation":[{"name":"Global Research, Sanofi Pasteur, 1541 Avenue Marcel M\u00e9rieux, Marcy l\u2019Etoile 69280, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaniv","family":"Lustig","sequence":"additional","affiliation":[{"name":"Central Virology Laboratory, Public Health Services, Israel Ministry of Health, Chaim Sheba Medical Center, Ramat Gan 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Institute of Geographic Medicine and Tropical Diseases, Sheba Medical Center, Ramat Gan, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A","family":"DiazGranados","sequence":"additional","affiliation":[{"name":"Global Clinical Sciences, Sanofi Pasteur, 1 Discovery Drive, Swiftwater PA 18370, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Savarino","sequence":"additional","affiliation":[{"name":"Translational Sciences and Biomarkers, Sanofi Pasteur, 1 Discovery Drive, Swiftwater PA 18370, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Ataman-\u00d6nal","sequence":"additional","affiliation":[{"name":"Translational Sciences and Biomarkers, Sanofi Pasteur, 1541 Avenue Marcel M\u00e9rieux, Marcy l\u2019Etoile 69280, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"2019122309081116200_ref1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global","year":"2017","journal-title":"Lancet"},{"key":"2019122309081116200_ref2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"2019122309081116200_ref3","first-page":"457","article-title":"Dengue vaccine: WHO position paper\u2014September 2018","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"2019122309081116200_ref4","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1016\/j.vaccine.2018.09.063","article-title":"WHO position paper, September 2018\u2014Recommendations","volume":"37","author":"Dengue vaccine","year":"2019","journal-title":"Vaccine"},{"key":"2019122309081116200_ref5","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1016\/j.vaccine.2019.07.016","article-title":"Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: a meeting report","volume":"37","author":"Wilder-Smith","year":"2019","journal-title":"Vaccine"},{"key":"2019122309081116200_ref6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cmi.2019.01.002","article-title":"Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews","volume":"25","author":"Luo","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2019122309081116200_ref7","volume-title":"Informing Vaccination Programs: a Guide to the Design and Conduct of Dengue Serosurveys","author":"World Health Organisation","year":"2017"},{"key":"2019122309081116200_ref8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1386-6532(00)00114-1","article-title":"Evaluation of ELISA-based sero-diagnosis of dengue fever in travelers","volume":"19","author":"Schwartz","year":"2000","journal-title":"J Clin Virol"},{"key":"2019122309081116200_ref9","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1016\/S2214-109X(18)30295-X","article-title":"Dengue vaccine: reliably determining previous exposure","volume":"6","author":"Arien","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2019122309081116200_ref10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/cid\/cix966","article-title":"Impact of dengue vaccination on serological diagnosis: insights from phase III dengue vaccine efficacy trials","volume":"66","author":"Plennevaux","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019122309081116200_ref11","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.vaccine.2016.04.028","article-title":"Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: utility for efficacy evaluation and impact of future vaccine introduction","volume":"34","author":"Plennevaux","year":"2016","journal-title":"Vaccine"},{"key":"2019122309081116200_ref12","doi-asserted-by":"crossref","first-page":"151967","DOI":"10.1155\/2012\/151967","article-title":"Commercial dengue rapid diagnostic tests for point-of-care application: recent evaluations and future needs?","volume":"2012","author":"Blacksell","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"2019122309081116200_ref13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4269\/ajtmh.15-0492","article-title":"Evaluation of commercially available assays for diagnosis of acute dengue in schoolchildren during an epidemic period in Medellin, Colombia","volume":"95","author":"Piedrahita","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2019122309081116200_ref14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12929-015-0164-9","article-title":"The performance of the SD BIOLINE Dengue DUO(R) rapid immunochromatographic test kit for the detection of NS1 antigen, IgM and IgG antibodies during a dengue type 1 epidemic in Jamaica","volume":"22","author":"Vickers","year":"2015","journal-title":"J Biomed Sci"},{"key":"2019122309081116200_ref15","first-page":"602","article-title":"Evaluation of a commercial rapid test kit for detection of acute dengue infection","volume":"46","author":"Krishnananthasivam","year":"2015","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2019122309081116200_ref16","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/JCM.03042-14","article-title":"Multicountry prospective clinical evaluation of two enzyme-linked immunosorbent assays and two rapid diagnostic tests for diagnosing dengue fever","volume":"53","author":"Pal","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2019122309081116200_ref17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.diagmicrobio.2013.12.019","article-title":"Evaluation of the SD BIOLINE Dengue Duo rapid test in the course of acute and convalescent dengue infections in a Mexican endemic region","volume":"78","author":"Sanchez-Vargas","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019122309081116200_ref18","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine","volume":"19","author":"Wilder-Smith","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2019122309081116200_ref19","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"2019122309081116200_ref20","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"2019122309081116200_ref21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/21645515.2015.1076598","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: a randomized, observer-blind, placebo-controlled phase II trial","volume":"12","author":"Dubey","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2019122309081116200_ref22","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2019122309081116200_ref23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"2019122309081116200_ref24","article-title":"Immune response to different schedules of a tetravalent dengue vaccine given with or without yellow fever vaccine","author":"Pasteur"},{"key":"2019122309081116200_ref25","article-title":"Immunologic mechanisms of immune interference and\/or cross-neutralizing immunity after CYD tetravalent dengue vaccine","author":"Pasteur"},{"key":"2019122309081116200_ref26","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1128\/JCM.00346-17","article-title":"Sensitivity and kinetics of an NS1-based Zika virus enzyme-linked immunosorbent assay in Zika virus-infected travelers from Israel, the Czech Republic, Italy, Belgium, Germany, and Chile","volume":"55","author":"Lustig","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2019122309081116200_ref27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"2019122309081116200_ref28","first-page":"639","article-title":"A guide to aid the selection of diagnostic tests","volume":"95","author":"Kosack","year":"2017","journal-title":"B Bull WHO"},{"key":"2019122309081116200_ref29","doi-asserted-by":"crossref","first-page":"18077","DOI":"10.1038\/srep18077","article-title":"Enhanced performance of an innovative dengue IgG\/IgM rapid diagnostic test using an anti-dengue EDI monoclonal antibody and dengue virus antigen","volume":"5","author":"Lee","year":"2015","journal-title":"Sci Rep"},{"key":"2019122309081116200_ref30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jviromet.2018.03.007","article-title":"Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus","volume":"257","author":"Nascimento","year":"2018","journal-title":"J Virol Methods"},{"key":"2019122309081116200_ref31","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.21.30237","article-title":"Letter to the editor: specificity of Zika virus ELISA: interference with malaria","volume":"21","author":"Van Esbroeck","year":"2016","journal-title":"Euro Surveill"},{"key":"2019122309081116200_ref32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pt.2013.03.002","article-title":"How malaria modulates memory: activation and dysregulation of B cells in plasmodium infection","volume":"29","author":"Scholzen","year":"2013","journal-title":"Trends Parasitol"},{"key":"2019122309081116200_ref33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/vim.2007.0050","article-title":"Antibody to dengue 1 detected more than 60 years after infection","volume":"20","author":"Imrie","year":"2007","journal-title":"Viral Immunol"},{"key":"2019122309081116200_ref34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1089\/biores.2016.0016","article-title":"Persistence of neutralizing antibody against dengue virus 2 after 70 Years from infection in Nagasaki","volume":"5","author":"Ngwe Tun","year":"2016","journal-title":"Biores Open Access"},{"key":"2019122309081116200_ref35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fcimb.2017.00317","article-title":"Global epidemiology of dengue outbreaks in 1990-2015: a systematic review and meta-analysis","volume":"7","author":"Guo","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"2019122309081116200_ref36","author":"World Health Organisation"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taz078\/30153683\/taz078.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jtm\/article-pdf\/26\/8\/taz078\/31605276\/taz078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jtm\/article-pdf\/26\/8\/taz078\/31605276\/taz078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T09:11:52Z","timestamp":1577092312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taz078\/5588085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,10,16]]},"published-print":{"date-parts":[[2019,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taz078","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019]]},"published":{"date-parts":[[2019]]},"article-number":"taz078"}}